Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 4/20 | 0.38 |
| ▸ | BCR | P11274 | 4/20 | 0.38 |
| ▸ | KMO | O15229 | 2/20 | 0.36 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10000744 | 0.83 | CCR1 (0.55) | CYP2A6CCR1CCR5CCR8METAP2 | |
| SCHEMBL29434061 | 0.83 | CCR1 (0.55) | CYP2A6CCR1CCR5CCR8METAP2 | |
| SCHEMBL20132633 | 0.82 | PIM1 (0.36) | CYP2A6TGFBR1 | |
| SCHEMBL13525158 | 0.82 | ALDH1A1 (0.41) | METAP2IDO1 | |
| SCHEMBL513232 | 0.81 | ALDH1A1 (0.44) | METAP2IDO1 | |
| SCHEMBL12761250 | 0.79 | GP6 (0.37) | IDO1 | |
| SCHEMBL6893920 | 0.77 | NR1H2 (0.38) | GRM5 | |
| SCHEMBL12408987 | 0.76 | CYP2A6 (0.65) | CYP2A6CCR1CCR5CCR8TGFBR1 | |
| SCHEMBL2479816 | 0.75 | CYP2A6 (0.59) | CYP2A6CCR1CCR5CCR8TGFBR1 | |
| SCHEMBL8117188 | 0.75 | KDM5A (0.34) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9096586-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | CYP2A6 2409/4885CCR1 886/4885CCR5 225/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | CYP2A6 855/4885CCR1 106/4885CCR5 3/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | CYP2A6 855/4885CCR1 106/4885CCR5 3/4885 |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | CYP2A6 2409/4885CCR1 886/4885CCR5 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.